VTP-27999 2,2,2-trifluoroacetateTopo II inhibitor CAS# 1013937-63-7 |
- FLAG tag Peptide
Catalog No.:BCC2562
CAS No.:98849-88-8
Quality Control & MSDS
Chemical structure
3D structure
Number of papers citing our products
| Cas No. | 1013937-63-7 | SDF | Download SDF |
| PubChem ID | 66577057 | Appearance | Powder |
| Formula | C28H42ClF3N4O7 | M.Wt | 639.1 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | VTP-27999 | ||
| Solubility | H2O : 10 mg/mL (15.65 mM; Need ultrasonic) | ||
| Chemical Name | methyl N-[2-[(3-chlorophenyl)-[(3R)-1-[[(2S)-2-(methylamino)-3-[(3R)-oxan-3-yl]propyl]carbamoyl]piperidin-3-yl]methoxy]ethyl]carbamate;2,2,2-trifluoroacetic acid | ||
| SMILES | CNC(CC1CCCOC1)CNC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC.C(=O)(C(F)(F)F)O | ||
| Standard InChIKey | SYWYSVAEGXHOJO-WHTVDMENSA-N | ||
| Standard InChI | InChI=1S/C26H41ClN4O5.C2HF3O2/c1-28-23(14-19-6-5-12-35-18-19)16-30-25(32)31-11-4-8-21(17-31)24(20-7-3-9-22(27)15-20)36-13-10-29-26(33)34-2;3-2(4,5)1(6)7/h3,7,9,15,19,21,23-24,28H,4-6,8,10-14,16-18H2,1-2H3,(H,29,33)(H,30,32);(H,6,7)/t19-,21-,23+,24?;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Highly potent and selective renin inhibitor (IC50 = 0.47 nM). Displays >1000-fold selectivity over related and unrelated off-targets. Blocks renin-stimulated ERK1/2 phosphorylation in vascular smooth muscle cells. Exhibits a different mode of action to aliskiren. | |||||
VTP-27999 2,2,2-trifluoroacetate Dilution Calculator
VTP-27999 2,2,2-trifluoroacetate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5647 mL | 7.8235 mL | 15.647 mL | 31.294 mL | 39.1175 mL |
| 5 mM | 0.3129 mL | 1.5647 mL | 3.1294 mL | 6.2588 mL | 7.8235 mL |
| 10 mM | 0.1565 mL | 0.7824 mL | 1.5647 mL | 3.1294 mL | 3.9118 mL |
| 50 mM | 0.0313 mL | 0.1565 mL | 0.3129 mL | 0.6259 mL | 0.7824 mL |
| 100 mM | 0.0156 mL | 0.0782 mL | 0.1565 mL | 0.3129 mL | 0.3912 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
VTP-27999, 2,2,2-trifluoroacetate (1:1) is useful for Hypertension and End-Organ Diseases.
- CP 376395 hydrochloride
Catalog No.:BCC7604
CAS No.:1013933-37-3
- Gadolinium chloride
Catalog No.:BCC7971
CAS No.:10138-52-0
- Formosanol
Catalog No.:BCN5826
CAS No.:101312-79-2
- PF-04691502
Catalog No.:BCC3837
CAS No.:1013101-36-4
- Zacopride hydrochloride
Catalog No.:BCC7178
CAS No.:101303-98-4
- Noreugenin
Catalog No.:BCN5827
CAS No.:1013-69-0
- PETCM
Catalog No.:BCC2360
CAS No.:10129-56-3
- 11-Chloro-2,3-dihydro-2-methyl-1H- dibenz[2,3:6,7]oxepino[4,5-c]pyrrol-1-one
Catalog No.:BCC8431
CAS No.:1012884-46-6
- Phenserine
Catalog No.:BCC7529
CAS No.:101246-66-6
- Kushenol M
Catalog No.:BCN3310
CAS No.:101236-51-5
- Kushenol L
Catalog No.:BCN3309
CAS No.:101236-50-4
- Kushenol K
Catalog No.:BCN3448
CAS No.:101236-49-1
- GSK 0660
Catalog No.:BCC7688
CAS No.:1014691-61-2
- 5''-O-Syringoylkelampayoside A
Catalog No.:BCN4798
CAS No.:1014974-98-1
- Methyl salvionolate A
Catalog No.:BCN3475
CAS No.:1015171-69-3
- Latifolin
Catalog No.:BCN7778
CAS No.:10154-42-4
- Fmoc-D-Pro-OH
Catalog No.:BCC3540
CAS No.:101555-62-8
- Yadanzioside K
Catalog No.:BCN6714
CAS No.:101559-98-2
- Yadanzioside M
Catalog No.:BCN6712
CAS No.:101559-99-3
- trans-2,3-Dihydro-3-ethoxyeuparin
Catalog No.:BCN6923
CAS No.:1015698-14-2
- GSK 4716
Catalog No.:BCC7557
CAS No.:101574-65-6
- 6-O-Nicotinoylbarbatin C
Catalog No.:BCN5828
CAS No.:1015776-92-7
- N-Acetyltryptamine
Catalog No.:BCC6618
CAS No.:1016-47-3
- Trenbolone
Catalog No.:BCC9183
CAS No.:10161-33-8
Renin inhibitor VTP-27999 differs from aliskiren: focus on their intracellular accumulation and the (pro)renin receptor.[Pubmed:24637873]
J Hypertens. 2014 Jun;32(6):1255-63.
BACKGROUND: VTP-27999 is a renin inhibitor with an IC50 that is comparable to that of aliskiren, but with a higher bioavailability. Unexpectedly, VTP-27999, unlike aliskiren, did not unfold renin's precursor, prorenin, and increased the affinity of the antibodies applied in renin immunoassays. METHODS: Here we verified to what degree these differences affect intracellular renin inhibitor accumulation in renin-synthesizing human mast cells (HMC-1), and (pro)renin's signaling via the (pro)renin receptor ((P)RR) in rat vascular smooth muscle cells. We also addressed the consequences of (P)RR knockdown by small-interfering (si) RNA on (pro)renin release. Finally, making use of FRET(Bodipy-FL)-labeled aliskiren, we studied, by subcellular fractionation, the cellular distribution pattern of this renin inhibitor. RESULTS: VTP-27999 accumulated at higher levels in HMC-1 cells than aliskiren, allowing this inhibitor to block intracellular renin at approximately five-fold lower medium levels. Labeled aliskiren accumulated in mitochondria and lysosomes, and its distribution pattern was different from that of renin. Moreover, the intracellular accumulation of both inhibitors in nonrenin-synthesizing HEK293 cells was not different from that in HMC-1 cells, suggesting that it is renin synthesis-independent. VTP-27999, but not aliskiren, blocked renin's capacity to stimulate extracellular signal-regulated kinase 1/2 phosphorylation in vascular smooth muscle cells, whereas neither inhibitor interfered with prorenin-induced signaling. (P)RR knockdown greatly increased renin (and to a lesser degree, prorenin) release, without affecting the capacity of forskolin or cAMP to stimulate renin release. CONCLUSION: VTP-27999 differs from aliskiren regarding its level of intracellular accumulation and its capacity to interfere with renin signaling via the (P)RR, and the (P)RR determines prorenin-renin conversion and constitutive (but not regulated) (pro)renin release.
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.[Pubmed:24900262]
ACS Med Chem Lett. 2011 Aug 9;2(10):747-51.
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.
